FGFR4 and hepatocellular carcinoma: The NCT02325739 trial led by Novartis Pharmaceuticals was an open-label study of oral FGF401 (roblitinib) in adult patients with HCC or solid malignancies characterized by positive FGFR4 and KLB expression [35].